A long term study for patients with Psoriasis to evaluate how well the oral pill, Tofacitinib (XELJAN2®) works and oversee the safety of its use.
A phase 3, multi-site, open-label study of the long term safety and tolerability of 2 oral doses of CP-690,550 in subjects with moderate to severe chronic plaque psoriasis
An additional 4 years of treatment for Psoriasis patients who have previously received Secukinumab (Cosentyx®) injections monthly. This study is looking at the safety and how wekk this medication works. Novartis Pharmaceuticals.
A multicenter, double-blind and open label, 4 year extension study of subcutaneous secukinumab in prefilled syringes, assessing long-term safety, tolerability and efficacy in subjects with moderate to severe chronic plaque-type psoriasis treated with either a fixed dose regimen or on a retreatment at start of relapse regimen.
A 1 year study for patients with Psoriasis to compare a biosimilar (CHS-0214) of Enbrel to Enbrel injections taken 1-2 times a week.
A double-blind, randomized, parallel-group, active-control study to compare the efficacy and safety of CHS-0214 Versus Enbrel® in subjects with chronic plaque Psoriasis (CHS-0214-04).
A 6 month study for patients with Psoriasis taking Enbrel injections 1-2 times a week. This is to compare a modified manufacturing process to the current production method.
A Single-arm study to assess the immunogenicity and safety of etanercept produced using a modified process in subjects with plaque psoriasis.
A 3 year continuation of treatment with weekly Dupilumab injections for patients who have previously taken this for Atopic Dermatitis.
A randomized, double-blind, placebo-controlled study to demonstrate the efficacy and long-term safety of Dupilumab in adult patients with moderate-to-severe atopic dermatitis.
A 1 year study for patients with Atopic Dermatitis testing weekly or bi-weekly injections with Dupilumab, or placebo. Testing longer term usage for how effective and safe it is.
An Open-label study of Dupilumab in patients with Atopic Dermatitis who participated in previous Dupilumab clinical trials.